Last Week Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Ratings

May 17, 2018 - By Robert Judd

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Corporate Logo

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Ratings Coverage

In total 2 analysts cover Collegium Pharmaceutical (NASDAQ:COLL). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. (NASDAQ:COLL) has 100% bullish analysts. 6 are the (NASDAQ:COLL)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. On Thursday, December 7 the firm has “Buy” rating given by Piper Jaffray. In Tuesday, January 23 report Piper Jaffray maintained it with “Buy” rating and $33.0 target. On Wednesday, November 29 the stock of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) earned “Buy” rating by Piper Jaffray. On Sunday, February 11 the stock of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) earned “Buy” rating by Jefferies. On Monday, February 12 the company was maintained by Piper Jaffray. On Thursday, December 14 Piper Jaffray maintained Collegium Pharmaceutical, Inc. (NASDAQ:COLL) with “Buy” rating. Listed here are Collegium Pharmaceutical, Inc. (NASDAQ:COLL) PTs and latest ratings.

12/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $33.0 Maintain
11/02/2018 Broker: Jefferies Rating: Buy New Target: $32.0 Maintain
23/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $33.0 Maintain
14/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $23.0 Maintain
07/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $24.0 Maintain
29/11/2017 Broker: Piper Jaffray Rating: Buy New Target: $19.0 Maintain

The stock increased 2.20% or $0.54 during the last trading session, touching $25.1.Currently Collegium Pharmaceutical, Inc. is uptrending after 133.98% change in last May 17, 2017. COLL has 186,789 shares volume. The stock outperformed the S&P 500 by 122.43%.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases.The company has $829.40 million market cap. It offers Xtampza, an oral formulation of oxycodone, for the management of pain.Last it reported negative earnings. The firm also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older.

For more Collegium Pharmaceutical, Inc. (NASDAQ:COLL) news published recently go to: Globenewswire.com, Globenewswire.com, Seekingalpha.com, Nasdaq.com or Benzinga.com. The titles are as follows: “Collegium Reports First Quarter Financial Results and Provides Corporate Update” published on May 09, 2018, “Collegium to Present at the Deutsche Bank Health Care Conference” on May 02, 2018, “FDA OKs first non-opioid treatment for opioid withdrawal” with a publish date: May 16, 2018, “Why Depomed Inc.’s Shares Soared 23.2% Higher” and the last “Benzinga’s Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway” with publication date: May 09, 2018.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.